Xenon Pharmaceuticals Inc. XENE reported a loss of 81 cents per share for the third quarter of 2024, narrower than the Zacks ...

Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025– Long-term azetukalner results from X-TOLE open-label ...

Xenon is currently developing azetukalner for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS), as well as major depressive ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...